Iza-bren improved survival and delayed disease progression versus chemotherapy in previously treated metastatic ...
A new study found that breast cancer deaths are increasingly affecting younger women, while survival rates have improved ...
Iza-bren is a potentially first-in-class bispecific ADC designed to target both EGFR and HER3. It features high affinity for ...
The Food and Drug Administration (FDA) on May 22, 2026, approved Datroway (datopotamab deruxtecan-dlnk) for adult patients ...
MedPage Today on MSN
New first-line option approved in triple-negative breast cancer
Datopotamab deruxtecan indicated for patients ineligible for immunotherapy ...
Phase III Tropion‑Breast02 demonstrated a 43% reduction in progression/death risk versus chemotherapy, with median overall ...
A first-in-class bispecific antibody-drug conjugate that Bristol Myers Squibb paid $800 million for has shown strong phase 3 ...
Breast cancer deaths, once concentrated mostly among older women, are now claiming younger women more often, researchers ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary ...
March 28, 2007 — A new study clearly reveals the survival disadvantage for the so-called "triple-negative" subtype of breast cancer compared with other types of breast cancer. These tumors test ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results